ERBB2 and gastric cancer: For gastric cancer, a phase 1b/2 trial of tucatinib plus trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2-positive gastrointestinal cancers is ongoing (NCT04430738).